Meyer T, Rustin G J
Department of Medical Oncology, Mount Vernon Hospital, Northwood, Middlesex, UK.
Br J Cancer. 2000 May;82(9):1535-8. doi: 10.1054/bjoc.2000.1174.
Currently the only tumour marker to have a well-defined and validated role in the management of ovarian cancer is CA125. Changes in the level of CA125 can be used as a reliable indication of response or progression according to various criteria, but it does not yet have a clear place in diagnosis or prognosis. Its value as part of a screening tool and during routine follow-up remain the subject of ongoing trials. Other markers remain experimental and do not have a well-defined contribution to make at present.
目前,在卵巢癌管理中唯一具有明确且经过验证作用的肿瘤标志物是CA125。根据各种标准,CA125水平的变化可作为反应或进展的可靠指标,但它在诊断或预后方面尚未有明确的地位。其作为筛查工具的一部分以及在常规随访期间的价值仍是正在进行的试验的主题。其他标志物仍处于实验阶段,目前尚无明确的贡献。